This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.
Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why
by Zacks Equity Research
The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $267.36, moving +0.07% from the previous trading session.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $267.18, moving -0.31% from the previous trading session.
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
by Zacks Equity Research
Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.
Biogen Inc. (BIIB) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues
by Zacks Equity Research
Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
by Zacks Equity Research
Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More
by Zacks Equity Research
Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.
Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.
Compared to Estimates, Biogen Inc. (BIIB) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Biogen Inc. (BIIB) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $276.17, marking a -0.8% move from the previous day.
Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression
by Zacks Equity Research
Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.
Earnings Preview: Biogen Inc. (BIIB) Q2 Earnings Expected to Decline
by Zacks Equity Research
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.
Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment
by Zacks Equity Research
Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $277.41, moving -0.87% from the previous trading session.
Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should iShares Morningstar Mid-Cap Value ETF (IMCV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCV
Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).